Antioxidant Strategies and Respiratory Disease of the Preterm Newborn: An Update

Table 1

Exogenous administration of rhSOD to preterm newborns with RDS.

Eligible population	Administration details	Outcomes	Reference
Preterm infants; BW 750–1250 g; <24 hrs of life; (𝑛=26)	Route: ET; Dose: 0.5 mg/Kg or 5 mg/Kg or saline, within 30 mins of surfactant, single dose	Reduced neutrophils chemotactic activity and albumin in tracheal aspirates in the high dose treatment group versus low dose or saline.	[39]
Preterm infants; BW 700–1300 g; <24 hrs of life; (𝑛=33)	Route: ET; Dose: 2.5 mg/Kg or 5 mg/Kg or saline, within 2 hrs of surfactant, up to 7 doses	Reduced neutrophils chemotactic activity and albumin in tracheal aspirates in the treatment groups versus saline.; No difference in BPD.	[40]
Long-term follow up of preterm infants enrolled in [39, 40]; (𝑛=46)	As in [39, 40]	No difference in neurodevelopmental disorder or chronic respiratory disorders at median of 28 months of corrected age.	[41]
Preterm infants; BW 600–1200 g; <24 hrs of life; (𝑛=302)	Route: ET; Dose: 5 mg/Kg or saline,; within 0.5–4 hrs of surfactant, repeated every 48 hrs until 28 days	No difference in BPD rate, days of mechanical ventilation, and oxygen requirement.; Reduced episodes of wheezing requiring bronchodilators or steroids in the treatment groups versus saline at 1-year follow-up.	[42]

BW: birth weight; ET: endotracheal.